-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Lowers Price Target to $62

Benzinga·05/14/2025 14:12:30
Listen to the news
Morgan Stanley analyst Vikram Purohit downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Equal-Weight and lowers the price target from $73 to $62.